Aytu BioPharma (NASDAQ:AYTU) had its price target raised by analysts at Ascendiant Capital Markets from $12.50 to $13.00. They now have a "buy" rating on the stock.
Aytu BioPharma (NASDAQ:AYTU) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ... [Yahoo! Finance]
Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript [Seeking Alpha]
Aytu BioPharma (NASDAQ:AYTU) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.